146 related articles for article (PubMed ID: 30601319)
21. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care.
Schäfer HH; Scheunert U
Swiss Med Wkly; 2013; 143():w13854. PubMed ID: 24163048
[TBL] [Abstract][Full Text] [Related]
22. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer.
Mandilaras V; Bouganim N; Yin H; Asselah J; Azoulay L
Br J Cancer; 2017 Jan; 116(1):103-108. PubMed ID: 27846200
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials.
Shahin Y; Khan JA; Samuel N; Chetter I
Atherosclerosis; 2011 May; 216(1):7-16. PubMed ID: 21411098
[TBL] [Abstract][Full Text] [Related]
24. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review.
Huang Y; Zhou Q; Haaijer-Ruskamp FM; Postma MJ
BMC Nephrol; 2014 Jan; 15():15. PubMed ID: 24428868
[TBL] [Abstract][Full Text] [Related]
26. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
[TBL] [Abstract][Full Text] [Related]
27. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
28. Incidence and factors associated with prescribing renin-angiotensin-system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study.
Nishiwaki H; Niihata K; Shimizu S; Shibagaki Y; Yamamoto R; Nitta K; Tsukamoto T; Uchida S; Takeda A; Okada H; Narita I; Isaka Y; Kurita N;
J Clin Hypertens (Greenwich); 2021 May; 23(5):999-1007. PubMed ID: 33645883
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation.
Zheng B; Kang J; Tian Y; Tang R; Long D; Yu R; He H; Zhang M; Shi L; Tao H; Liu X; Dong J; Ma C
Acta Cardiol; 2009 Jun; 64(3):335-40. PubMed ID: 19593943
[TBL] [Abstract][Full Text] [Related]
31. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
[TBL] [Abstract][Full Text] [Related]
32. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study.
Marott SC; Nielsen SF; Benn M; Nordestgaard BG
Eur Heart J; 2014 May; 35(18):1205-14. PubMed ID: 24347316
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
[TBL] [Abstract][Full Text] [Related]
34. Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population.
Mohd-Tahir NA; Li SC
PLoS One; 2019; 14(2):e0212832. PubMed ID: 30817790
[TBL] [Abstract][Full Text] [Related]
35. Is preoperative chemoradiation in rectal cancer patients modulated by ACE inhibitors? Results from the Dutch Cancer Registry.
Rombouts AJ; Hugen N; Verhoeven RH; Kuiper JG; Poortmans PM; de Wilt JH; Nagtegaal ID
Radiother Oncol; 2019 Sep; 138():86-92. PubMed ID: 31252299
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
[TBL] [Abstract][Full Text] [Related]
37. Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE).
Al-Zakwani I; Sulaiman K; Al-Lawati JA; Alsheikh-Ali AA; Panduranga P; Al-Habib KF; Al Suwaidi J; Al-Mahmeed W; Al-Faleh H; Elasfar A; Al-Motarreb A; Ridha M; Bulbanat B; Al-Jarallah M; Bazargani N; Asaad N; Amin H
Curr Vasc Pharmacol; 2018; 16(6):596-602. PubMed ID: 28820057
[TBL] [Abstract][Full Text] [Related]
38. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC
Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426
[TBL] [Abstract][Full Text] [Related]
39. Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension.
Ahad A; Al-Mohizea AM; Al-Jenoobi FI; Aqil M
Drug Deliv; 2016; 23(2):579-90. PubMed ID: 25065883
[TBL] [Abstract][Full Text] [Related]
40. Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
Swamy KM; Lin MJ; Sun CM
Mini Rev Med Chem; 2003 Sep; 3(6):621-31. PubMed ID: 12871164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
